CM
AGIO icon

Crestline Management’s Agios Pharmaceuticals AGIO Stock Holding History

Crestline Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,105
Closed -$595K – 24
2024
Q4 		$595K Buy
+18,105
New +$851K 0.02% 504
2018
Q1 		– Sell
-23,727
Closed -$1.36M – 214
2017
Q4 		$1.36M Sell
23,727
-5,298
-18% -$333K 0.14% 79
2017
Q3 		$1.94M Buy
+29,025
New +$1.74M 0.27% 70
2017
Q1 		– Sell
-7,778
Closed -$325K – 115
2016
Q4 		$325K Buy
+7,778
New +$408K 0.08% 65

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Crestline Management's AGIO Position: Q1 2025 in Review

Crestline Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2025, closing a stake of 18,105 shares — an estimated $595K sold.

Crestline Management first reported a position in AGIO in Q4 2016 and held it in 4 quarters. The position peaked at $1.94M in Q3 2017. 220 funds tracked by Wall St. Rank hold AGIO as of Q1 2025.

  • Crestline Management reported no remaining Agios Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 18,105 Agios Pharmaceuticals shares in Q1 2025, an estimated $595K.
  • Crestline Management first reported a position in Agios Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Crestline Management's Agios Pharmaceuticals position peaked at $1.94M in Q3 2017.
  • 220 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.